source
- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…Endpoints · 3mo ago↗ source
- Biotech layoffs are easing, but is the worst over?BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.BioPharma Dive · 3mo ago↗ source
- European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapyDrug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to becom…Endpoints